Abstract
Previous case reports have shown the promising antitumor activity of everolimus in solid tumors containing molecular aberrations in PI3K/ATK/mTOR pathway, however, whether it is effective in patients with breast cancer remains unknown. Therefore, we conducted this retrospective cohort study to compare the efficacy of molecularly matched targeted therapy with everolimus to conventional therapy in refractory breast cancer patients harboring PI3K/ATK/mTOR pathway activating mutations. Refractory metastatic breast cancer patients who have received molecular screening using next-generation sequencing (NGS) between September 8, 2015 and October 30, 2017 in two sites were screened for this study. The primary outcome was progression-free survival (PFS). The secondary outcomes were overall response rate (ORR), disease control rate (DCR), and safety profile. A total of 78 patients were screened for analysis, amongst all, 52 (66.7%) had at least one gene mutation in PI3K/AKT/mTOR pathway. The most common mutation fell in PIK3CA (76.9%, 40/52) with a mutational prevalence of 51.3%. Of the 32 patients who were eligible for efficacy analysis, patients in the everolimus group (n = 19) exhibited shorter PFS than those in the conventional group...Continue Reading
References
May 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Sherene LoiChristos Sotiriou
Sep 4, 2010·The American Journal of Pathology·Francisco J EstevaDihua Yu
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffRobert Penny
Dec 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bhuvanesh DaveJenny C Chang
Jun 5, 2012·Cancer Treatment Reviews·Sara A HurvitzRichard S Finn
Sep 12, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Apostolia-Maria TsimberidouRazelle Kurzrock
Feb 11, 2014·The Lancet Oncology·Fabrice AndréHervé Bonnefoi
Apr 20, 2014·The Lancet Oncology·Fabrice AndréLuca Gianni
Sep 12, 2014·Breast Cancer Research and Treatment·Gayle S JamesonNicholas J Robert
Sep 12, 2014·Cancer·Rafeek A YusufFunda Meric-Bernstam
Apr 18, 2015·BMC Cancer·Ji Hyun ParkYoon-Koo Kang
Jun 21, 2015·The Lancet Oncology·Sara A HurvitzDennis Slamon
Sep 8, 2015·The Lancet Oncology·Christophe Le TourneauUNKNOWN SHIVA investigators
Oct 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriel N HortobagyiJosé Baselga
Feb 10, 2016·Oncotarget·Sun Min LimByoung Chul Cho
Apr 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabrice AndréDennis Slamon
Jul 26, 2016·OncoTargets and Therapy·Bing SunSantai Song
Nov 30, 2016·Cancer Metastasis Reviews·Angel Guerrero-ZotanoCarlos L Arteaga
Dec 9, 2016·JAMA Oncology·Howard Jack West
Feb 10, 2017·Journal of Hematology & Oncology·Sophie CousinAntoine Italiano
Feb 10, 2017·British Journal of Cancer·Mary Ellen MoynahanSarat Chandarlapaty
Apr 4, 2017·Cancer Discovery·Christophe MassardJean-Charles Soria
May 28, 2017·Cold Spring Harbor Molecular Case Studies·Christine A ParachoniakJuliann Chmielecki
Sep 9, 2017·Journal of Experimental & Clinical Cancer Research : CR·Dan SuFugen Li
Nov 1, 2017·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Kazuhiro Araki, Yasuo Miyoshi
Nov 28, 2017·Breast Cancer Research and Treatment·Rossanna C PezoPhilippe L Bedard
Dec 30, 2017·Journal of breast cancer·Zongbi Yi, Fei Ma
Mar 7, 2018·Journal of Experimental & Clinical Cancer Research : CR·Matteo AllegrettiPatrizio Giacomini
Mar 24, 2018·BMC Cancer·Nong YangFugen Li